<DOC>
	<DOCNO>NCT00606541</DOCNO>
	<brief_summary>Purpose Study : To examine 1 ) short long-term effectiveness tolerability quetiapine ( extended release ) XR treatment social anxiety disorder ( SAD ) ; 2 ) continuation effect quetiapine XR prevent SAD relapse .</brief_summary>
	<brief_title>An Open Label , Double-blind Discontinuation Study Quetiapine Extended Release ( XR )</brief_title>
	<detailed_description />
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Adults 1865 year age A primary diagnosis SAD , use Diagnostic Standard Manual IV ( DSMIV ) criteria Minimum CGI severity score 4 minimum Brief Social Phobia Scale ( BSPS ) score 20 baseline Written inform consent A negative serum pregnancy test woman childbearing potential . Current DSMIV diagnosis bipolar disorder , schizophrenia psychotic disorder , mental retardation pervasive developmental disorder , cognitive disorder due general medical condition Any current primary anxiety disorder SAD current primary depression History substance abuse dependence within last 6 month Suicide risk serious suicide attempt within last year Clinically significant medical condition laboratory abnormality Women childbearing potential unwilling practice acceptable method contraception Subjects need concurrent use psychotropic medication History hypersensitivity quetiapine History cataract .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Social Anxiety Disorder</keyword>
	<keyword>Quetiapine XR</keyword>
	<keyword>Prevention</keyword>
	<keyword>tolerability</keyword>
</DOC>